Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights

Wagdy M. Eldehnaa School of Biotechnology, Badr University in Cairo, Badr City, Egypt;b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, EgyptCorrespondence[email protected]
View further author information

Raed M. Makladb Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt;c Institute of Drug Discovery and Development, Kafrelsheikh University, Kafrelsheikh, EgyptView further author information

Hadia Almahlid Department of Chemistry, University of Cambridge, Cambridge, UKView further author information

Tarfah Al-Warhie Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaView further author information

Eslam B. Elkaeedf Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi ArabiaView further author information

Mohammed A. S. Abourehabg Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaView further author information

Hatem A. Abdel-Azizh Department of Applied Organic Chemistry, National Research Center, Dokki, EgyptView further author information

Ahmed M. El Kerdawyi Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt;j Department of Pharmaceutical Chemistry, School of Pharmacy, NewGiza University (NGU), Cairo, EgyptView further author information

show all

Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date